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Abstract
Fragile X-associated tremor ataxia syndrome (FXTAS) is a late onset neurodegenerative disease
that affects carriers of the fragile X premutation. This study seeks to assess hypertension risk and
susceptibility in male premutation carriers with FXTAS. Although many symptoms and diagnostic
criteria have been identified, hypertension risk has not been examined in this population. Data
from 92 premutation carriers without FXTAS, 100 premutation carriers with FXTAS, and 186
controls was collected via patient medical interview. Age-adjusted logistic regression analysis was
used to examine the relative odds of hypertension. We observed a significantly elevated odds ratio
(OR) of hypertension relative to controls for premutation carriers with FXTAS (OR = 3.22, 95%
CI: 1.72–6.04; P = 0.0003) among participants over 40-year old. The age-adjusted estimated odds
of hypertension in premutation carriers without FXTAS in the over 40-year-old age group was
higher compared to controls (OR = 1.61, 95% CI: 0.82–3.16), but was not statistically significant
(P = 0.164). Chronic hypertension contributes to cardiovascular complications, dementia, and
increased risk of stroke. Our results indicate that the risk of hypertension is significantly elevated
in male premutation carriers with FXTAS compared with carriers without FXTAS and controls.
Thus, evaluation of hypertension in patients diagnosed with FXTAS should be a routine part of the
treatment monitoring and intervention for this disease.
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Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disease found
in carriers of the premutation (55–200 CGG repeats) at the 5′-end of the fragile X mental
retardation 1 (FMR1) gene. It has been estimated that one-third of male pre-mutation
carriers over 50 years [Jacquemont et al., 2004a] and approximately 8–16% of female
carriers develop FXTAS [Coffey et al., 2008; Rodriguez-Revenga et al., 2009].
Diagnostic criteria describing FXTAS have been reported [Jacquemont et al., 2003;
Hagerman and Hagerman, 2004]. The major clinical phenotype of FXTAS is intention
tremor and gait ataxia, but parkinsonism, moderate-to-severe short-term memory deficiency,
and executive function deficits are also commonly seen [Loesch et al., 2005a; Grigsby et al.,
2006; Berry-Kravis et al., 2007]. There are also psychiatric aspects of FXTAS, including
depression, anxiety, irritability, and apathy [Bacalman et al., 2006; Bourgeois et al., 2009,
2011]. MRI features of FXTAS include white matter lesions involving the subcortical and
periventricular regions and the middle cerebellar peduncles (MCP) [Brunberg et al., 2002].
The presence of this MCP sign is observed in approximately 60% of affected males and 13%
of affected females [Adams et al., 2007]. However, this sign is not specific for FXTAS, and
not all patients with FXTAS develop the MCP sign. Cerebral, brainstem, and cerebellar
volume loss compared to age-matched controls is observed [Loesch et al., 2005b; Cohen et
al., 2006; Adams et al., 2007].
Neuropathological findings of FXTAS include intranuclear inclusions in neurons and
astrocytes throughout the brain [Greco et al., 2006] and in the peripheral nervous system
[Gokden et al., 2009]. The inclusions are likely caused by an RNA gain-of-function effect
from elevated FMR1-mRNA in the premutation [Hagerman and Hagerman, 2004]. The
excess mRNA appears to sequester additional proteins, including an RNA-binding protein
involved in splicing regulation, Sam 68. Dysfunction of Sam 68 leads to mis-splicing of
mRNAs, including that of the SMN gene that is mutated in spinal muscular atrophy [Sellier
et al., 2010].
Autonomic dysfunction has been widely noted in patients with FXTAS. Erectile dysfunction
typically begins before the onset of tremor and ataxia while other autonomic dysfunction,
such as bladder and bowel incontinence, occur late in the course of FXTAS [Greco et al.,
2007]. Hypertension has been reported in over 60% of females with FXTAS, a significant
increase compared to age-matched controls [Coffey et al., 2008]. Preliminary data suggest
that this problem is not uncommon in males with FXTAS [Hagerman and Hagerman, 2004;
Jacquemont et al., 2004b]. Here, we explore hypertension in males with the premutation,
with and without FXTAS, compared with age-matched controls.
MATERIALS AND METHODS
Subjects
Over the last 3 years data from 192 adult premutation carrier males and 186 adult male
controls contributed to this study. Most of the patients were recruited through three studies
taking place at the MIND Institute at the University of California, Davis. The study
protocols involved a medical history and physical examination that routinely included blood
pressure measurement. In addition, data on 32 males (9 controls and 23 premutation carriers)
was collected from Melbourne, Australia at the La Trobe University. Controls are mostly
family members of patients with the fragile X mutation or individuals recruited to the MIND
by staff and faculty. All data used in this study is from consented patients participating in
research protocols both at the MIND as well as in Australia.
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The 192 premutation carriers were divided into two groups based on their FXTAS diagnosis.
Individuals were considered to have FXTAS if they met criteria for definite or probable
FXTAS according to the most recent classifications as defined by Jacquemont et al. [2003].
This assessment includes both radiological and clinical symptoms. The two groups analyzed
were 92 premutation carriers without FXTAS and 100 premutation carriers with FXTAS.
METHODS
Clinical data including hypertension, blood pressure, and age of onset of hypertension was
gathered during a medical appointment or interview. For most patients, a self-reported
diagnosis of hypertension by another physician was sufficient to consider them having
hypertension. Alternatively, at the MIND Institute, any patient with a blood pressure
measurement over 140/90 taken during the appointment was also considered hypertensive.
Lastly, any patient on blood pressure medication was categorized to have hypertension
diagnosed by the prescribing physician, even if a normal blood pressure measurement was
reported during the examination.
All blood pressure values for this study are those directly measured during examinations
rather than being self-reported by the patient. For patients with multiple visits to the MIND
and thus with multiple blood pressure measurements, the latest observation was used in
order to have a single data entry for each patient.
Age of onset of hypertension was also recorded or self-reported during the medical
examination and was typically the age when the patient began to take antihypertensive
medication.
Molecular Analysis
CGG repeat status was used as the basis to determine premutation carriers and controls.
Patients with repeat numbers between 55 and 200 were considered to be premutation carriers
while those with 50 repeats or less were considered controls. Gray zone patients (51–54
repeats) and mosaics were not used in this study. Blood samples were analyzed utilizing the
methods outlined by Tassone et al. [2000, 2004] and Saluto et al. [2005]. Determination of
trinucleotide expansion was completed using an Alpha Innotech FlourChem 8800 Image
Detection System.
Statistical Analysis
Comparison of patient characteristics among groups was based on analysis of variance
(ANOVA) for continuous variables and Fisher’s exact test for categorical variables,
completed separately for individuals below and above age 40 years. To examine the
association between hypertension and the patients group (control, premutation with FXTAS,
and premutation without FXTAS), logistic regression model adjusted for age was used. The
results are presented in terms of odds ratios (OR) and 95% confidence intervals (CI).
Because hypertension is correlated with age, our model adjusts for age of individuals.
RESULTS
Patient Characteristics
Premutation carriers without FXTAS ranged in age from 18 to 84 years, with a mean of
51.28 (SD = 16.94 years), and were divided into two groups, age 18–39 and 40–84. All
premutation carriers with FXTAS were above age 40, with a range of 52–89 and an average
age of 67 years (SD = 7.58 year). Controls ranged in age from 19 to 88 years, had an
average age of 47 (SD = 15.58 years) and were also divided into two age groups (Table I).
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The average age of controls and premutation carriers without FXTAS in the 18–40 age
range was not statistically significantly different (P = 0.276), with controls averaging 32
years and premutation carriers averaging 30 years. However, age is significantly different
between controls (mean 56, SD 11.08) and premutation carriers without FXTAS in the over
40 age range (mean 60, SD 12.18; P = 0.021). The premutation individuals with FXTAS
(mean 67, SD 7.58) were significantly older than controls and premutation carriers without
FXTAS in the over 40 range (P <0.0001, respectively). Characteristics of participants are
provided in Table I.
Hypertension in Premutation Carriers With and Without FXTAS
Among 18- to 40-year-old subjects, 1 of the 27 premutation carriers without FXTAS
(3.70%) and 11 out of 69 controls (15.94%) had hypertension. However, the difference was
not statistically significant (P = 0.134). Among 65 over 40-year-old premutation carriers
without FXTAS, 27 (41.54%) had hypertension while 38 (58.46%) did not. In contrast,
among the 117 controls, 32 (27.35%) had hypertension; 85 (72.65%) did not (Table II).
Although the age-adjusted estimated risk of hypertension in premutation carriers without
FXTAS in the over 40 age group was higher compared to controls (OR = 1.61, 95% CI:
0.82–3.16), this was not statistically significant (P = 0.164).
In 100 over 40-year-old premutation males with FXTAS, 67 (67%) had hypertension while
only 33 (33%) did not. The age-adjusted OR of hypertension relative to controls was OR =
3.22 (CI: 1.72–6.04) and was statistically significant (P = 0.0003). Age was positively
associated with hypertension with approximately 6% increased odds for a 1 year increase in
age (OR = 1.062, 95% CI: 1.03–1.09; P <0.0001).
Blood Pressure
Because many patients suffering from hypertension took medication to lower their blood
pressure, blood pressure values were not significantly different between any group and their
age-matched controls. The average measurements taken for controls, premutation carriers
without FXTAS and premutation carriers with FXTAS were 130.4/80.2, 132.2/78.9, and
135.8/77.0, respectively (Table I).
Age of Onset of Hypertension
Based on limited availability of data regarding age of onset, there appears to be little
difference between both premutation groups compared to age-matched controls, although we
emphasize that this should be considered descriptive only. There is limited data available for
controls and premutation carriers without FXTAS, with only 11 and 6 records for the age of
onset, respectively. This is compared to the 38 age of onset records for premutation carriers
with FXTAS. Also due to the onset of hypertension later in life, we had age of onset data
only for patients older than 40 years. Controls had an average age of onset of 56,
premutation carriers without FXTAS of 54, and premutation carriers with FXTAS of 53
years. Since our study lacks sufficient data on hypertension onset and contributing factors,
further studies are needed to delineate the age of onset of hypertension in premutation
carriers, including modifying factors.
DISCUSSION
Hypertension and related autonomic dysfunction have been discussed as symptoms of
FXTAS in previous publications [Jacquemont et al., 2003, 2004b; Coffey et al., 2008];
however, extensive controlled studies in males have not been performed. Coffey et al.
[2008] reported hypertension as significantly more common in female carriers with FXTAS
compared to controls, but not so in premutation carriers without FXTAS. Based on the data
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collected in this study, a similar result was found in males. There is a significantly higher
age-adjusted risk (odds) of hypertension associated with FXTAS compared to controls
among male subjects over age 40 years. However, the odds of hypertension in premutation
carriers without FXTAS were not different from controls. It should be noted that in this
study and in Coffey et al. [2008], medical data were collected via self-report, along with
documentation of medication to treat hypertension. Potential bias resulting from this data
collection method is limited by the similarity of the collection methods used for patients and
age-matched controls.
The cause of hypertension is likely related to the autonomic dysfunction seen in FXTAS
[Jacquemont et al., 2003; Leehey, 2009]. These problems may be related to the inclusion
involvement of the peripheral nervous system, including both sympathetic and
parasympathetic ganglia and pericardial ganglia [Gokden et al., 2009]. However, centers in
the brain coordinating autonomic responses, including the insula, thalamus, and
hypothalamus, are also affected by white matter disease [Greco et al., 2006, 2008;
Hashimoto et al., 2011].
In addition, individuals with the premutation with and without FXTAS often have
depression, anxiety, and other psychiatric problems [Hessl et al., 2005; Bourgeois et al.,
2009, 2011; Leehey, 2009], which may also be related to elevated blood pressure. Although
the precise correlation between hypertension and depression has yet to be established, they
often occur together [Scalco et al., 2005]. Depressive symptoms, anxiety, and stress are
associated with elevated corticosteroid levels. Premutation mice have an elevated
corticosteroid response to stress when they age, and it is likely that this also occurs in
humans with the premutation [Brouwer et al., 2008].
Untreated hypertension can result in cardiovascular complications, dementia, and an
increased risk of stroke [Perry et al., 2000; Chobanian et al., 2003; Nagai et al., 2010]. More
controversially, chronic hypertension may result in an increased incidence of white matter
disease [Sierra and Coca, 2006; Gottesman et al., 2010]. Treatment of hypertension and
subsequent reduction of blood pressure can slow the progression of white matter disease,
and thus in turn reduce the risk of stroke and increasing dementia [Godin et al., 2011]. These
benefits may also be seen in those with FXTAS who are treated for their hypertension and
thus deserves further study.
There are a number of interventions that can treat hypertension in FXTAS carriers. Attention
to the psychiatric problems and daily stresses should be discussed. Antidepressants,
including selective serotonin reuptake inhibitors (SSRIs), which can also stimulate
neurogenesis, can be utilized to treat depression or anxiety in addition to psychotherapy
[Hagerman et al., 2008; Bourgeois et al., 2009]. Behavioral treatment of hypertension
includes weight loss, salt restriction, exercise, and a healthy diet with reduced cholesterol
and fat intake. When lifestyle adjustments are not enough to lower blood pressure, medical
and pharmacological treatments are used [Chobanian et al., 2003].
There is currently no cure for FXTAS. However, treatment options for cognitive decline,
tremor, gait ataxia, and other FXTAS symptoms have been reported [Hagerman et al., 2008;
Berry-Kravis et al., 2010]. Elevated hypertension risk has been established in female
premutation carriers with FXTAS [Coffey et al., 2008]. This study supports the same
outcome for males. Therefore, all pre-mutation carriers with FXTAS should be screened for
hypertension and treated as needed.
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TABLE I
Participant Characteristics
Age <40 Age ≥40 All data
N Mean (SD) N Mean (SD) N Mean (SD)
Group
 Pre with FXTAS — — 100 67.19 (7.58) 100 67.19 (7.58)
 Pre without FXTAS 27 30.21 (7.15) 65 60.02 (11.06) 92 51.28 (16.94)
 Control 69 31.98 (5.25) 117 56.26 (12.18) 186 47.22 (15.58)
Age <40 Age ≥40 All data
N*/N Mean (SD) N*/N Mean (SD) N*/N Mean (SD)
SBP
 Pre with FXTAS — — 88/100 135.78 (18.33) 88/100 135.78 (18.33)
 Pre without FXTAS 23/27 123.39 (11.26) 44/65 136.73 (14.5) 67/92 132.15 (14.83)
 Control 56/69 126.27 (13.33) 90/117 133.01 (14.36) 146/186 130.42 (14.31)
DBP
 Pre with FXTAS — — 88/100 76.95 (8.8) 88/100 76.95 (8.8)
 Pre without FXTAS 23/27 73.91 (12.93) 44/65 81.45 (7.99) 67/92 78.87 (10.51)
 Control 56/69 79.13 (8.67) 90/117 80.89 (8.38) 146/186 80.21 (8.51)
N, number of subjects in group; N*, number of blood pressure measurements collected in group; SBP, systolic blood pressure; DBP, diastolic
blood pressure.
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TABLE II
Hypertension in Subjects Age ≥40 Years
Hypertension
TotalAbsent Present
Pre with FXTAS 33 (33.0%) 67 (67.0%) 100
Pre without FXTAS 38 (58.5%) 27 (41.5%) 65
Control 85 (72.6%) 32 (27.4%) 117
Total 156 (55.3%) 126 (44.7%) 282
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